ArticleAmerican journal of preventive cardiology2025
Under-recognized cardiovascular risk enhancers in women: A call to rethink clinical assessment on risk stratification.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Modeling of Coronary Artery Disease Using Color Fundus Photography-Based Features of Retinal Vasculature.Ophthalmology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Traditional cardiovascular risk (CVR) stratification does not consider CVR enhancers (CVRE). Women present under-recognized CVRE factors that may lead to arterial stiffness (AS). AS is associated with long-term cardiovascular disease. AS can be determined by carotid-femoral pulse wave velocity (cf-PWV). In women with low-CVR and a CVRE, our objective was to determine cf-PWV values and AS, and to compare with a control group. Material and Methods: Multicentric cross-sectional study, from 2022 to 2024 in Argentina. Included women between 18 and 59 years-old, without traditional CVR-factors, low (<5 %) 10-year CVR, and office blood-pressure (BP) <140/90 mmHg. Inclusion criteria: Group 1: presence of a CVRE (history of gestational hypertension, preeclampsia; autoimmune rheumatic or hematological disease in clinical remission; previous oncological treatment in current complete remission; history of abortions; early menopause or menarche; anxiety or depression disorder; human immunodeficiency virus infected virally suppressed). Group-2: women who attended routine control. Exclusion criteria: hypertension; diabetes; target organ damage; chronic kidney disease; current smoking; history of CV-event; statins, aspirin, or antihypertensive treatment. Results: Included 280 women: Group-1 (N = 174); Group-2 (N = 106). Group-1 showed higher cf-PWV: 7.02±1.20 vs. 5.71±0.86 ( Conclusions: Women with CVRE showed greater cf-PWV and higher frequency of AS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.